Hospital
Mclaren Bay Region
Mclaren Bay Region was paid $31.72M by Medicaid between Jan 2018 and Dec 2024, across 385 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoMCLAREN BAY REGION
BAY CITY, MI 48708
BAY CITY, MI 48708
33aNPI1528031226assigned 02/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$31.72M
24GClaims1,134,930
24DCodes billed385
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#36 of 86
Median peer was paid$21.55M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JACKS PORTER, DANIELLE controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 140,749 | $5.02M | |
| 2019 | 162,584 | $4.80M | |
| 2020 | 146,106 | $4.24M | |
| 2021 | 185,290 | $4.69M | |
| 2022 | 178,089 | $4.58M | |
| 2023 | 180,227 | $4.62M | |
| 2024incomplete | 141,885 | $3.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 32,670 | 30,379 | $5.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 37,795 | 35,502 | $4.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 15,913 | 14,800 | $4.58M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 16,541 | 15,146 | $1.32M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.9% | 38,770 | 30,841 | $1.25M |
| 93458 | 2.3% | 699 | 657 | $731K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 8,481 | 8,166 | $715K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 24,887 | 6,620 | $654K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 2.0% | 3,614 | 3,102 | $649K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 4,823 | 4,704 | $639K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 5,947 | 5,730 | $449K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 2,456 | 2,404 | $445K |
373 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 4,350 | $408K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 4,893 | $404K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 2,492 | $353K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 10,374 | $352K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 13,866 | $348K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 10,163 | $340K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 10,446 | $337K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.0% | 743 | $317K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,347 | $287K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,032 | $268K |
| 20610 | <1% | 1,884 | $248K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,125 | $245K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 2,410 | $242K |
| A0425 | Ground mileage, per statute mile | <1% | 7,764 | $223K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 733 | $197K |
| 59025 | Fetal non-stress test | <1% | 2,362 | $196K |
| 80061 | Lipid panel | <1% | 17,477 | $192K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 497 | $176K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,046 | $175K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 334 | $159K |
| 97161 | <1% | 3,341 | $151K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,857 | $147K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,537 | $145K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 555 | $138K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,682 | $136K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 1,348 | $131K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 573 | $114K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,058 | $109K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 217 | $95K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,211 | $92K |
| 82947 | <1% | 3,600 | $91K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,652 | $90K |
| 73564 | <1% | 4,245 | $88K | |
| G0378 | Hospital observation service, per hour | <1% | 2,760 | $81K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,541 | $76K |
| 93971 | <1% | 1,537 | $73K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 926 | $66K |
| 72110 | <1% | 2,815 | $65K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,250 | $64K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 567 | $64K |
| 95811 | <1% | 145 | $60K | |
| 62323 | <1% | 213 | $59K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,531 | $59K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,189 | $56K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,995 | $55K |
| 93017 | <1% | 1,453 | $53K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,331 | $51K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,327 | $50K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,995 | $49K |
| 80053 | Comprehensive metabolic panel | <1% | 59,433 | $48K |
| 72141 | <1% | 361 | $42K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,440 | $41K |
| 73030 | <1% | 3,515 | $40K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,701 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 68,893 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,290 | $37K |
| 72100 | <1% | 1,264 | $37K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,407 | $37K |
| 73630 | <1% | 3,738 | $36K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,012 | $36K |
| 76642 | <1% | 992 | $34K | |
| 96367 | <1% | 1,056 | $34K | |
| 74018 | <1% | 1,710 | $33K | |
| 73610 | <1% | 3,212 | $33K | |
| 76801 | <1% | 623 | $32K | |
| 95910 | <1% | 233 | $31K | |
| 93975 | <1% | 300 | $31K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,489 | $30K |
| 93880 | <1% | 317 | $30K | |
| 73130 | <1% | 3,199 | $27K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 38 | $26K |
| 86900 | <1% | 4,014 | $25K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 102 | $25K |
| 76536 | <1% | 523 | $25K | |
| 96127 | <1% | 2,517 | $24K | |
| 73110 | <1% | 2,396 | $24K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 47,925 | $24K |
| 71250 | <1% | 509 | $24K | |
| 73502 | <1% | 1,758 | $24K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,239 | $23K |
| 72050 | <1% | 793 | $22K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,216 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,154 | $21K |
| 93970 | <1% | 212 | $20K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,020 | $20K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 352 | $20K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 77 | $20K |
| 73221 | <1% | 164 | $19K | |
| 71271 | <1% | 347 | $19K | |
| 76775 | <1% | 560 | $18K | |
| 76641 | <1% | 378 | $17K | |
| 90677 | <1% | 50 | $14K | |
| 94726 | <1% | 397 | $14K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 683 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,546 | $14K |
| 76770 | <1% | 272 | $13K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 224 | $13K |
| 77066 | Tomosynthesis, mammo | <1% | 234 | $13K |
| 64493 | <1% | 28 | $12K | |
| 90686 | <1% | 775 | $12K | |
| 73562 | <1% | 868 | $12K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,294 | $12K |
| 70486 | <1% | 397 | $11K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 1,193 | $11K |
| 94060 | <1% | 84 | $11K | |
| 97162 | <1% | 212 | $10K | |
| 72072 | <1% | 584 | $9K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 40 | $9K |
| 82607 | <1% | 4,684 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,530 | $9K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 777 | $8K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 356 | $8K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 44 | $8K |
| 84439 | <1% | 6,806 | $8K | |
| 97165 | <1% | 165 | $8K | |
| 72131 | <1% | 202 | $8K | |
| 73080 | <1% | 843 | $7K | |
| 95806 | <1% | 96 | $7K | |
| 71101 | <1% | 664 | $7K | |
| 96415 | <1% | 187 | $7K | |
| 77065 | Tomosynthesis, mammo | <1% | 164 | $7K |
| 90670 | <1% | 214 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,710 | $6K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 525 | $6K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,706 | $6K |
| 82728 | <1% | 2,871 | $5K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 232 | $5K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 290 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 642 | $5K |
| 72040 | <1% | 240 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,378 | $4K |
| 83880 | <1% | 3,122 | $4K | |
| 85610 | <1% | 19,256 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,697 | $4K |
| 96523 | <1% | 152 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 343 | $3K |
| 74022 | <1% | 2,102 | $3K | |
| 82746 | <1% | 1,710 | $3K | |
| 96376 | <1% | 3,047 | $3K | |
| 93296 | <1% | 189 | $3K | |
| 87077 | <1% | 3,516 | $3K | |
| 87390 | <1% | 890 | $3K | |
| 87186 | <1% | 3,202 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,725 | $3K |
| 87070 | <1% | 3,234 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 26 | $3K |
| 90474 | <1% | 455 | $3K | |
| 83540 | <1% | 3,133 | $3K | |
| 83550 | <1% | 2,264 | $3K | |
| 80076 | <1% | 2,092 | $3K | |
| 82570 | <1% | 3,336 | $3K | |
| 84702 | <1% | 2,588 | $2K | |
| 20553 | <1% | 17 | $2K | |
| 97035 | <1% | 584 | $2K | |
| 76882 | <1% | 54 | $2K | |
| 83735 | <1% | 8,169 | $2K | |
| 87660 | <1% | 793 | $2K | |
| 96417 | <1% | 77 | $2K | |
| 87480 | <1% | 736 | $2K | |
| 87510 | <1% | 736 | $2K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 314 | $2K |
| 74019 | <1% | 51 | $2K | |
| 80074 | <1% | 282 | $2K | |
| 82043 | <1% | 2,739 | $2K | |
| 76000 | <1% | 162 | $2K | |
| 81001 | <1% | 18,939 | $2K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 240 | $2K |
| 86140 | <1% | 3,789 | $2K | |
| 73590 | <1% | 395 | $2K | |
| 70496 | <1% | 39 | $2K | |
| 86038 | <1% | 1,292 | $2K | |
| 95908 | <1% | 13 | $2K | |
| 86702 | <1% | 911 | $2K | |
| 83970 | <1% | 228 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,635 | $2K |
| 85027 | <1% | 3,356 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 357 | $2K |
| 95819 | <1% | 14 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,681 | $2K |
| 73140 | <1% | 169 | $2K | |
| 86850 | <1% | 3,927 | $2K | |
| 73090 | <1% | 328 | $1K | |
| 82565 | <1% | 1,616 | $1K | |
| 93299 | <1% | 77 | $1K | |
| 86803 | <1% | 642 | $1K | |
| 10060 | <1% | 17 | $1K | |
| 86701 | <1% | 908 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 26 | $1K |
| 99406 | <1% | 69 | $1K | |
| 83655 | <1% | 614 | $998.01 | |
| 85730 | <1% | 9,997 | $986.95 | |
| 84403 | <1% | 211 | $933.85 | |
| 83690 | <1% | 9,874 | $904.22 | |
| 72170 | <1% | 126 | $841.39 | |
| 84550 | <1% | 1,236 | $837.65 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 14 | $801.65 |
| 83721 | <1% | 425 | $760.62 | |
| A9270 | Non-covered item or service | <1% | 35,995 | $753.49 |
| 80164 | <1% | 306 | $687.15 | |
| 85652 | <1% | 2,232 | $684.42 | |
| 90688 | <1% | 68 | $668.88 | |
| 77080 | <1% | 12 | $657.23 | |
| 84156 | <1% | 1,201 | $653.69 | |
| 81003 | <1% | 9,818 | $632.95 | |
| 82150 | <1% | 3,539 | $627.58 | |
| 87205 | <1% | 1,478 | $614.48 | |
| 29581 | <1% | 25 | $595.06 | |
| 84450 | <1% | 813 | $565.12 | |
| 84460 | <1% | 751 | $548.01 | |
| 86901 | <1% | 4,515 | $544.69 | |
| 84100 | <1% | 1,269 | $539.88 | |
| 93225 | <1% | 12 | $536.84 | |
| 84703 | <1% | 861 | $507.40 | |
| 86431 | <1% | 720 | $488.85 | |
| 87340 | <1% | 301 | $443.09 | |
| 84153 | <1% | 91 | $432.10 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 104 | $422.17 |
| 81025 | <1% | 8,600 | $395.59 | |
| 93293 | <1% | 25 | $383.96 | |
| 73560 | <1% | 17 | $380.78 | |
| 72114 | <1% | 13 | $358.79 | |
| 86780 | <1% | 102 | $357.33 | |
| 82550 | <1% | 977 | $347.75 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,160 | $345.28 |
| 93922 | <1% | 12 | $332.90 | |
| 87147 | <1% | 546 | $308.66 | |
| 90656 | <1% | 18 | $288.45 | |
| 85379 | <1% | 2,195 | $277.29 | |
| 84484 | <1% | 12,488 | $267.45 | |
| 84520 | <1% | 320 | $265.25 | |
| 87634 | <1% | 773 | $265.22 | |
| 87040 | <1% | 2,406 | $254.21 | |
| 87081 | <1% | 1,971 | $243.85 | |
| 94729 | <1% | 372 | $227.80 | |
| 93280 | <1% | 13 | $207.19 | |
| 88142 | <1% | 162 | $205.10 | |
| 82077 | <1% | 4,956 | $198.94 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 181 | $192.31 |
| 85651 | <1% | 583 | $183.28 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,323 | $175.72 |
| 80143 | <1% | 2,826 | $172.30 | |
| 83516 | <1% | 59 | $148.12 | |
| 82248 | <1% | 103 | $146.68 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 58 | $141.36 |
| 88341 | <1% | 14 | $141.00 | |
| 86480 | <1% | 14 | $134.57 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 12 | $121.92 |
| 80179 | <1% | 2,529 | $121.70 | |
| 84146 | <1% | 48 | $113.84 | |
| 87522 | Neg quan hep c or qual rna | <1% | 14 | $112.88 |
| 12001 | <1% | 747 | $106.59 | |
| 83615 | <1% | 178 | $101.79 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,371 | $100.15 |
| 88342 | <1% | 149 | $95.55 | |
| 83605 | <1% | 4,033 | $95.22 | |
| 82652 | <1% | 27 | $90.95 | |
| 76870 | <1% | 77 | $87.60 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 12 | $77.04 |
| 87075 | <1% | 221 | $75.34 | |
| 80051 | <1% | 70 | $69.76 | |
| 82247 | <1% | 57 | $65.78 | |
| 86200 | <1% | 38 | $58.88 | |
| 81015 | <1% | 82 | $58.14 | |
| Q3014 | Telehealth originating site facility fee | <1% | 28 | $57.36 |
| 86592 | <1% | 66 | $56.80 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,400 | $55.84 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 143 | $49.78 |
| 80178 | <1% | 68 | $48.78 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,967 | $47.12 |
| 87046 | <1% | 24 | $41.92 | |
| 85046 | <1% | 57 | $39.43 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 100 | $38.39 |
| 82140 | <1% | 68 | $37.90 | |
| 84481 | <1% | 16 | $31.77 | |
| J3490 | Unclassified drugs | <1% | 11,699 | $31.38 |
| 85018 | <1% | 80 | $28.04 | |
| 82803 | <1% | 102 | $26.89 | |
| 87427 | <1% | 13 | $26.63 | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 32 | $26.08 |
| 87045 | <1% | 13 | $20.96 | |
| 84165 | <1% | 13 | $16.61 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 283 | $14.73 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,074 | $13.53 |
| 86308 | <1% | 30 | $13.32 | |
| 84132 | <1% | 45 | $12.85 | |
| 87210 | <1% | 130 | $11.49 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,291 | $10.34 |
| 99152 | <1% | 1,408 | $7.13 | |
| 85007 | <1% | 18 | $6.72 | |
| 84436 | <1% | 39 | $6.44 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 911 | $5.83 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 720 | $5.66 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,850 | $4.34 |
| 85045 | <1% | 14 | $2.93 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,951 | $2.87 |
| 85014 | <1% | 17 | $2.66 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,460 | $0.05 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 3,820 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 3,535 | $0.00 |
| 94760 | 0% | 152 | $0.00 | |
| 95886 | 0% | 1,119 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 568 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 83 | $0.00 |
| C1769 | Guide wire | 0% | 931 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 5,964 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 1,083 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 152 | $0.00 |
| 93320 | 0% | 246 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 2,619 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 3,191 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 1,462 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 3,788 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 4,199 | $0.00 |
| 90716 | 0% | 12 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 1,263 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 234 | $0.00 |
| 90647 | 0% | 100 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 3,365 | $0.00 |
| 64494 | 0% | 44 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 252 | $0.00 |
| 90723 | 0% | 120 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 176 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 234 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 20 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 285 | $0.00 |
| 70498 | 0% | 25 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 114 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 122 | $0.00 |
| 12002 | 0% | 107 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 29 | $0.00 |
| 99024 | 0% | 56 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 44 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 30 | $0.00 |
| 88307 | 0% | 28 | $0.00 | |
| 96368 | 0% | 18 | $0.00 | |
| 82962 | 0% | 16 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 60 | $0.00 |
| 94010 | 0% | 14 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 3,102 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 111 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 3,423 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 5,271 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 75 | $0.00 |
| 90715 | 0% | 2,076 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 149 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 407 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 3,169 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 348 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 113 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 2,070 | $0.00 |
| 87220 | 0% | 102 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 16 | $0.00 |
| 93325 | 0% | 293 | $0.00 | |
| 29125 | 0% | 184 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 297 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 70 | $0.00 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 93 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 644 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 120 | $0.00 |
| 82010 | 0% | 88 | $0.00 | |
| 93226 | 0% | 12 | $0.00 | |
| 12011 | 0% | 66 | $0.00 | |
| 90681 | 0% | 13 | $0.00 | |
| 76942 | 0% | 47 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 26 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 224 | $0.00 |
| 94664 | 0% | 83 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 163 | $0.00 |
| 64495 | 0% | 44 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 66 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 34 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJACKS PORTER, DANIELLE (VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Mclaren Bay Region | Bay City, MI | $9.34M |
| Mclaren Bay Region | Bay City, MI | $937K |
| Mclaren Bay Region | Essexville, MI | $288K |
| Mclaren Primary Care | West Branch, MI | $250K |
| Mclaren Primary Care | Saint Helen, MI | $115K |
| Mclaren Bay Region | Saginaw, MI | $101K |
| Mclaren Primary Care | Alger, MI | $99K |
| Mclaren Primary Care | Mio, MI | $67K |
| Mclaren Primary Care | Rose City, MI | $42K |
| Mclaren Bay Region | Bay City, MI | $40K |
| Mclaren Primary Care | West Branch, MI | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.